New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2013
12:19 EDTVRX, WFT, LUFK, OMPI, FTK, JNJ, BCRX, GEOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as investors await the start of the latest earnings season, which kicks off unofficially after today's close with Alcoa's (AA) report. The averages all fell into negative ground soon after the open and found a level, from which they have been range-bound ever since. With a very quiet economic calendar today and generally depressed expectations for the earnings seasons, the lackluster trading may extend from here until the close... ECONOMIC EVENTS: In the U.S., no major economic data was reported... COMPANY NEWS: General Electric (GE) agreed to acquire Lufkin (LUFK), which supplies products, technology and services to the oil and gas industry, for $3.3B, or $88.50 per share in cash. Lufkin soared over 37% to trade within 50c of the agreed upon per share price at midday, while some of its peers rose as well, including Flotek (FTK) and Weatherford (WFT), which both advanced over 3%. GE shares, meanwhile, slid 0.4%... MAJOR MOVERS: Among the notable gainers was BioCryst (BCRX), which rose 22% amid reports of new bird flu infections in China. BioCryst is developing peramivir, an investigational anti-viral agent to treat influenza. Among the noteworthy losers was Obagi Medical (OMPI), which fell 6% after Merz Pharma withdrew its offer to acquire Obagi in the face of a $24 per share competing offer from Valeant Pharmaceuticals (VRX). Also lower were shares of Johnson & Johnson (JNJ), which slid nearly 2% after JPMorgan lowered it rating on the stock to Neutral from Overweight... INDICES: Near noon, the Dow was down 51.84, or 0.36%, to 14,513.41; the Nasdaq was down 3.11, or 0.10%, to 3,200.75; and the S&P 500 was down 1.63, or 0.10%, to 1,551.65.
News For LUFK;GE;FTK;WFT;BCRX;OMPI;VRX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
06:06 EDTVRXValeant raises FY15 cash EPS to $11.50-$11.80 from $10.90-$11.20
The increased EPS guidance reflects continued business outperformance and approval of IBS-D indication for Xifaxan. Raises FY15 total revenue to $10.7B-$10.4B from $10.4B-$10.6B. Sees FY15 Salix revenue $1.2B. Raises FY15 adjusted cash flow from operations to be greater than $3.2B from greater than $3.1B. Sees FY15 SSS organic growth of greater than 10% for 2H15.
06:05 EDTVRXValeant sees Q4 cash EPS $3.98-$4.18, revenue $3.2B-$3.4B
Subscribe for More Information
06:05 EDTVRXValeant sees Q3 cash EPS $2.60-$2.70, revenue $2.6B-$2.8B
Subscribe for More Information
06:04 EDTVRXValeant reports Q2 GAAP EPS (15c), Q2 cash EPS $2.56
Excluding negative impact of ForEx and Salix, cash EPS would have been $2.73. Reports Q2 total revenue $2.73B vs. $2.04B last year. Reports Q2 Product sales $2.70B vs. $1.99B last year. Reports Q2 SSS organic growth up 19%. Reports Q2 Salix revenue $313M.
July 22, 2015
19:55 EDTWFTWeatherford says market conditions will not significantly improve this year
Subscribe for More Information
19:54 EDTWFTWeatherford reduces FY15 capex forecast to $750M
Subscribe for More Information
19:53 EDTWFTWeatherford announces further headcount reduction
Weatherford said, "Because of the continuing weak North American market conditions, we plan to further reduce our cost structure to reflect the current environment. During Q2, we successfully completed substantially all of the previously announced headcount reduction of 10,000. The aggregate results of these measures will help mitigate the effects of the downturn, while at the same time, take advantage of the opportunity to develop a leaner structure and a tighter organization. This target has now been revised upward to 11,000 with the increase principally in the U.S with a focus on support positions. Our procurement savings initiative continues to be on track. In addition to our headcount reductions, this quarter, we closed three of our manufacturing and service facilities. We have also closed over 60 operating facilities across North America through the first half of 2015 and plan to close 30 more by the end of the year. All the while, quality, safety and reliability in execution will remain paramount."
19:50 EDTWFTWeatherford reports Q2 EPS (10c), consensus (12c)
Subscribe for More Information
16:23 EDTFTKFlotek sees profitable growth for 2H15
While we are very pleased with our second quarter results, we understand that cyclical headwinds remain which will continue to provide challenges to our industry in the coming months," concluded CEO Chisholm. "However, as our second quarter results show, a more difficult environment has created an opportunity for Flotek to demonstrate the importance of performance adding technology in maximizing operator performance and, as a result new opportunities for Flotek's advanced chemistry technologies. Through the use of FracMax and the 'Flotek Store', we believe the third quarter should build on the success of the last three months and provide opportunities for profitable growth in the second half of the year."
16:22 EDTFTKFlotek reports Q2 adjusted EPS 2c, consensus (7c)
Subscribe for More Information
15:26 EDTWFTNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Qualcomm (QCOM), consensus 95... American Express (AXP), consensus $1.32... Texas Instruments (TXN), consensus 65c... Las Vegas Sands (LVS), consensus 61c... Crown Castle (CCI), consensus $1.06... Discover Financial (DFS), consensus $1.32... Tractor Supply (TSCO), consensus $1.11... SanDisk (SNDK), consensus 33c... SL Green Realty (SLG), consensus $1.56... Xilinx (XLNX), consensus 54c... Weatherford (WFT), consensus (12c)... F5 Networks (FFIV), consensus $1.60... United Rentals (URI), consensus $1.74... Fortinet (FTNT), consensus 9c... LaSalle Hotel (LHO), consensus 89c... Oceaneering International (OII), consensus 68c... Cheesecake Factory (CAKE), consensus 62c.
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
07:23 EDTGEFrench minister 'reassured' by elements of Alstom, GE deal talks, Reuters says
Subscribe for More Information
July 21, 2015
10:01 EDTVRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 20, 2015
16:20 EDTGEFederal Reserve establishes enhanced standards for GE Capital
Subscribe for More Information
16:15 EDTVRXValeant initiated with a Buy at BTIG
Subscribe for More Information
09:04 EDTGEGE chooses Microsoft Office 365 fro employee collaboration and productivity
Subscribe for More Information
08:38 EDTVRXAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTVRXValeant price target raised to $285 from $275 at Canaccord
Subscribe for More Information
06:16 EDTGEAlstom sees General Electric deal completed in coming months, Reuters reports
Alstom (ALSMY) expects to complete the transaction with GE (GE) in the coming months, Reuters reports. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use